M&T Bank’s PTC Therapeutics PTCT Stock Holding History

M&T Bank’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$373K	Buy	4,573 +197	+5%	+$14.2K	﹤0.01%	1352
2026 Q1	$298K	Buy	4,376 +115	+3%	+$8.14K	﹤0.01%	1375
2025 Q4	$324K	Buy	+4,261	New	+$310K	﹤0.01%	1359

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

M&T Bank's PTCT Position: Q2 2026 in Review

M&T Bank increased its PTC Therapeutics (PTCT) stake by 4.5% in Q2 2026, buying an estimated $14.2K and bringing the position to 4,573 shares worth $373K. The position accounts for ﹤0.01% of the portfolio, ranked #1352.

M&T Bank first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

M&T Bank held 4,573 shares of PTC Therapeutics worth $373K as of Q2 2026.
M&T Bank bought 197 PTC Therapeutics shares in Q2 2026, an estimated $14.2K.
PTC Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #1352 holding.
M&T Bank first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.